Source - SMW
NetScientific said one of its portfolio companies, Glycotest, has been granted a Japanese patent for its core technology for early detection of life threatening liver disease.

Glycotest now holds a total of six patents in Australia, the US and Japan, covering the use of over 50 unique glycoprotein biomarkers for the diagnosis of liver cancers and other liver diseases.